| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh, Osteoporosis Prevention and Treatment Center, Department of Medicine, University of Pittsburgh, Departments of Health and Community Systems, Biostatics, and Epidemiology, School of Nursing and Graduate School of Public Health, University of Pittsburgh, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University
* To whom correspondence should be addressed. E-mail: GriffithsD{at}msx.dept-med.pitt.edu.
Nail patella syndrome (NPS), a rare autosomal dominant disorder resulting from a heterogenous loss of function in the LMX1B gene. It is associated with multiple skeletal deformities, yet it is unknown whether this is associated with osteoporosis. To examine bone mass and the prevalence of fragility fractures, we assessed bone mineral density (BMD) of the spine and hip in 31 adults and 12 children with mutation-confirmed NPS and 60 healthy, age- and gender-matched adult controls. For the adults with NPS, BMD was 11-20% lower at the hip sites (P
0.001) and 8% lower at the spine (P < 0.05) than that of controls. Even when adjusted for BMI, the BMD remained significantly lower in patients with NPS in all hip regions, but not in the spine. Adults with NPS also had a significantly lower Z-score (SDs from normal) at all hip sites (all P < 0.05) compared with age- and gender-matched controls in the manufacturer's database. However, children only had significantly lower Z-scores at the femoral neck and trochanter. Participants with NPS also had a higher prevalence of fractures (odds ratio = 30.9, 95% confidence interval = 6.4-149.6P < 0.001) and scoliosis (odds ratio =16.0, 95% confidence interval = 3.3-78.2P < 0.001). The majority of these fractures occurred in women before puberty and in long bones, especially the clavicle. We conclude that adults with NPS have a BMD that is 8-20% lower than controls, which is associated with an increase in the prevalence of fractures and scoliosis. Future studies are needed to determine if bone quality, geometry, or turnover could account for these findings.
This article has been cited by other articles:
![]() |
S. L. Greenspan, A. Brufsky, B. C. Lembersky, R. Bhattacharya, K. T. Vujevich, S. Perera, S. M. Sereika, and V. G. Vogel Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Clin. Oncol., June 1, 2008; 26(16): 2644 - 2652. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Greenspan, R. K. Bhattacharya, S. M. Sereika, A. Brufsky, and V. G. Vogel Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 131 - 136. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |